Ratings HitGen Inc.

Equities

688222

CNE1000040G3

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
12.22 ^CNY	-1.05%		-6.57%	-18.48%

Apr. 24	HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

With an expected P/E ratio at 96.47 and 79.7 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
HITGEN INC.	-18.48%	674M	-
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B	B+
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B	B+
BIONTECH SE	-8.14%	23.4B	B+
ARGENX SE	-1.11%	21.78B	B
GENMAB A/S	-9.10%	18.09B	A-
WUXI APPTEC CO., LTD.	-41.25%	16.72B	A-
BEIGENE, LTD.	-15.33%	15.97B	B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B	C+
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes